Zyrifa, a prescription drug, is manufactured in various forms such as Capsule. Primarily, it is used for the treatment of Tuberculosis.
The optimal dosage of Zyrifa is largely dependent on the individual's body weight, medical history, gender and age. The condition it has been prescribed for, and the route of administration also determine the right dosage. For detailed information on this, read through the dosage section.
The most common side effects of Zyrifa are Hallucinations, Disorientation, Confusion. Some other side effects of Zyrifa have been listed ahead. Normally, these side effects of Zyrifa are not long lasting and go away when the treatment is finished. Consult your doctor if these side effects become worse or stay for a longer duration.
In addition, Zyrifa's effect is Moderate during pregnancy and Unknown for lactating mothers. It is important to know if Zyrifa has any effect on the kidney, liver and heart. Information on such adverse effects, if any, has been given in the Zyrifa related warnings section.
Other contraindications of Zyrifa have been discussed in the sections ahead.
Drug interactions for Zyrifa have been reported in the medical literature. See below for a complete list.
Along with the above-mentioned precautions, remember that taking Zyrifa is considered not safe while driving, and is not addictive.
Zyrifa is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
Is the use of Zyrifa safe for pregnant women?
Zyrifa may have some side effects during pregnancy. Pregnant women should discontinue the use of Zyrifa, and talk to their doctor, if they notice any discomfort.
Is the use of Zyrifa safe during breastfeeding?
In the absence of any scientific study about the side effects of Zyrifa in breastfeeding women, information on safety of Zyrifa is unavailable.
What is the effect of Zyrifa on the Kidneys?
There may be some adverse effects on kidney after taking Zyrifa. If you observe any such side effects, stop taking this drug. Consume this medicine again only if your doctor advises you to do so.
What is the effect of Zyrifa on the Liver?
You may experience side effects on your liver after taking Zyrifa. If this happens, then discontinue its use. Consult your medical practitioner, do as he/she suggests.
What is the effect of Zyrifa on the Heart?
No research work has been carried out till date on effects of Zyrifa on heart. So it is not known whether taking Zyrifa will cause side effects on heart or not.
Zyrifa should not be taken with following medicines due to severe side effects it may cause to patients -
Moderate
If you are suffering from any of the following diseases, you should not take Zyrifa unless your doctor advises you to do so -
Is this Zyrifa habit forming or addictive?
Zyrifa is not addictive in nature.
Is it safe to drive or operate heavy machinery when consuming?
After taking Zyrifa you may feel sleepy. So it is not advised to perform these activities.
Is it safe?
Zyrifa is safe but it is important to consult a doctor before taking it.
Is it able to treat mental disorders?
There is no benefit of taking Zyrifa for mental disorders.
Interaction between Food and Zyrifa
Information is not available on the interaction of any foods with Zyrifa, due to a lack of research on this.
Interaction between Alcohol and Zyrifa
Consult your doctor before consuming alcohol while taking Zyrifa as it can have severe side effects.
This medicine data has been created by -
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Rifadin (rifampin)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 767-768
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Isoniazid
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 765-767
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 715-716
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Myambutol (ethambutol hcl)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 769
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 535-536
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 768-769
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1066-1067
